Aurora Cannabis Inc. is open to considering an acquisition offer from a U.S. cannabis company aiming to take over the Edmonton-based firm. The company announced the formation of a special committee to review the unsolicited bid shortly after Curaleaf Holdings Inc. disclosed its intention to acquire all shares of Aurora.
If successful, this acquisition would result in the creation of a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets, as per Curaleaf. The Stamford, Conn.-based company, listed on the Toronto Stock Exchange, revealed its public offer after unsuccessful private negotiations with Aurora’s leadership.
Curaleaf stated that Aurora’s board declined to engage in discussions following a formal acquisition proposal from Curaleaf’s CEO, Boris Jordan, on June 23. Despite a follow-up letter sent on July 7, Aurora allegedly did not participate in constructive talks. Consequently, Curaleaf plans to involve Aurora shareholders directly to proceed with the proposed transaction.
In response, Aurora confirmed receiving the letters from Curaleaf but disputed the claim of refusing to engage with the offer. The Canadian company’s lead independent director communicated with Curaleaf’s CEO as recently as July 24, expressing Aurora’s focus on executing its business plan while remaining open to ongoing dialogue.
Aurora will establish a special committee of independent directors to evaluate the proposal’s alignment with stakeholders’ interests. However, the company cautioned that a deal is not guaranteed, and it will continue normal operations during the process.
Although Curaleaf’s interest is viewed positively, TD Cowen analysts Derek Lessard and Ryan Neal believe that the current offer undervalues Aurora’s long-term potential. They emphasized the company’s market leadership in medical cannabis, robust product portfolio, financial strength, and capability to navigate global regulatory challenges as factors contributing to its significant value over time.
Curaleaf’s CEO, Jordan, emphasized that merging the two companies would leverage Curaleaf’s global distribution network with Aurora’s strong international medical cannabis presence and production capabilities. The combined entities recorded over $1.5 billion in revenue in the past year, with Curaleaf expecting annual cost synergies of at least $40 million post-acquisition.
Jordan expressed confidence that the merger would benefit both Curaleaf and Aurora shareholders, offering an opportunity for Aurora investors to access a diversified global platform and capitalize on U.S. regulatory developments.